Clinical Trial Update: Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of camrelizumab and fluzoparib for TP53-mutated endometrial cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Endometrial Carcinoma, TP53 Mutation | Phase 2 | Status: RECRUITING